Menu
← Oncology Approval Tracker
FDA DECISION ·
Thalidomide capsules (50, 100 and 200 mg)
thalidomide · Natco Pharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Final generic approval of the 50, 100 and 200 mg Thalomid capsule strengths. The oncology use is thalidomide with dexamethasone for newly diagnosed multiple myeloma.
LAMPGEN ANALYSIS
Why it matters
FDA granted final approval for these three strengths in 2026 and approved the 150 mg strength in 2023. The action adds generic capsule strengths for an established myeloma use.
What research teams should watch
Review current product access and applicable safety requirements for teratogenic risk before discussing availability or pharmacy substitution.
PRIMARY RECORDS